• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Nov 1999; 58(Suppl 1): I49–I55.
PMCID: PMC1766580

Tumour necrosis factor and other cytokines in murine lupus

Full Text

The Full Text of this article is available as a PDF (111K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996 Oct 31;383(6603):787–793. [PubMed]
  • Rincón M, Flavell RA. T-cell subsets: transcriptional control in the Th1/Th2 decision. Curr Biol. 1997 Nov 1;7(11):R729–R732. [PubMed]
  • Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997 May 16;89(4):587–596. [PubMed]
  • Chow CW, Rincón M, Davis RJ. Requirement for transcription factor NFAT in interleukin-2 expression. Mol Cell Biol. 1999 Mar;19(3):2300–2307. [PMC free article] [PubMed]
  • Rincón M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 1998 May 15;17(10):2817–2829. [PMC free article] [PubMed]
  • Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med. 1998 Nov 16;188(10):1859–1866. [PMC free article] [PubMed]
  • Altman A, Theofilopoulos AN, Weiner R, Katz DH, Dixon FJ. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med. 1981 Sep 1;154(3):791–808. [PMC free article] [PubMed]
  • Dauphinée MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol. 1981 Dec;127(6):2483–2487. [PubMed]
  • Tanaka T, Nagasaka Y, Kitamura F, Kuida K, Suwa H, Miyasaka M. The role of the interleukin-2 (IL-2)/IL-2 receptor pathway in MRL/lpr lymphadenopathy: the expanded CD4-8- T cell subset completely lacks functional IL-2 receptors. Eur J Immunol. 1993 Jun;23(6):1378–1380. [PubMed]
  • Clements JL, Cooper SM, Budd RC. Abnormal regulation of the IL-2 promoter in lpr CD4-CD8- T lymphocytes results in constitutive expression of a novel nuclear factor of activated T cells-binding factor. J Immunol. 1995 Jun 15;154(12):6372–6381. [PubMed]
  • Liang HE, Hsueh YP, Wu CC, Hsu SC, Han SH, Lai MZ. Atypical signaling defects prevent IL-2 gene expression in lpr/lpr CD4-CD8- cells. J Biomed Sci. 1998 Jul-Aug;5(4):297–304. [PubMed]
  • Balomenos D, Rumold R, Theofilopoulos AN. The proliferative in vivo activities of lpr double-negative T cells and the primary role of p59fyn in their activation and expansion. J Immunol. 1997 Sep 1;159(5):2265–2273. [PubMed]
  • Sabzevari H, Propp S, Kono DH, Theofilopoulos AN. G1 arrest and high expression of cyclin kinase and apoptosis inhibitors in accumulated activated/memory phenotype CD4+ cells of older lupus mice. Eur J Immunol. 1997 Aug;27(8):1901–1910. [PubMed]
  • Clements JL, Wolfe J, Cooper SM, Budd RC. Reversal of hyporesponsiveness in lpr CD4-CD8- T cells is achieved by induction of cell cycling and normalization of CD2 and p59fyn expression. Eur J Immunol. 1994 Mar;24(3):558–565. [PubMed]
  • Huang FP, Stott DI. Restoration of an early, progressive defect in responsiveness to T-cell activation in lupus mice by exogenous IL-2. Autoimmunity. 1993;15(1):19–29. [PubMed]
  • Radvanyi LG, Raju K, Spaner D, Mills GB, Miller RG. Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. Cell Immunol. 1998 Jan 10;183(1):1–12. [PubMed]
  • Gutierrez-Ramos JC, Andreu JL, Revilla Y, Viñuela E, Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature. 1990 Jul 19;346(6281):271–274. [PubMed]
  • Huggins ML, Huang FP, Xu D, Lindop G, Stott DI. Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier. Lupus. 1999;8(1):29–38. [PubMed]
  • Raz E, Dudler J, Lotz M, Baird SM, Berry CC, Eisenberg RA, Carson DA. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus. 1995 Aug;4(4):286–292. [PubMed]
  • Owen KL, Shibata T, Izui S, Walker SE. Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse. J Biol Response Mod. 1989 Aug;8(4):366–374. [PubMed]
  • Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol. 1988 Jan 1;140(1):59–61. [PubMed]
  • Bocchieri MH, Knittweis L, Seaton DS. Cytokine production by NZB, C58, and NZB X C58 recombinant inbred mice. Cell Immunol. 1984 Oct 15;88(2):453–463. [PubMed]
  • Davidson WF, Roths JB, Holmes KL, Rudikoff E, Morse HC., 3rd Dissociation of severe lupus-like disease from polyclonal B cell activation and IL 2 deficiency in C3H-lpr/lpr mice. J Immunol. 1984 Aug;133(2):1048–1056. [PubMed]
  • Abe C, Koyama A, Nishimura T. Interleukin-2 induction, response and therapy on murine lupus lesions in the MRL/l strain. Prog Clin Biol Res. 1987;229:147–156. [PubMed]
  • Sadlack B, Löhler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol. 1995 Nov;25(11):3053–3059. [PubMed]
  • Suzuki H, Kündig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science. 1995 Jun 9;268(5216):1472–1476. [PubMed]
  • Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995 Oct;3(4):521–530. [PubMed]
  • Davidson WF, Calkins C, Hügins A, Giese T, Holmes KL. Cytokine secretion by C3H-lpr and -gld T cells. Hypersecretion of IFN-gamma and tumor necrosis factor-alpha by stimulated CD4+ T cells. J Immunol. 1991 Jun 15;146(12):4138–4148. [PubMed]
  • Prud'homme GJ, Kono DH, Theofilopoulos AN. Quantitative polymerase chain reaction analysis reveals marked overexpression of interleukin-1 beta, interleukin-1 and interferon-gamma mRNA in the lymph nodes of lupus-prone mice. Mol Immunol. 1995 May;32(7):495–503. [PubMed]
  • Shirai A, Conover J, Klinman DM. Increased activation and altered ratio of interferon-gamma: interleukin-4 secreting cells in MRL-lpr/lpr mice. Autoimmunity. 1995;21(2):107–116. [PubMed]
  • Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med. 1987 Sep 1;166(3):798–803. [PMC free article] [PubMed]
  • Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol. 1995 Jan;25(1):6–12. [PubMed]
  • Takahashi S, Fossati L, Iwamoto M, Merino R, Motta R, Kobayakawa T, Izui S. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J Clin Invest. 1996 Apr 1;97(7):1597–1604. [PMC free article] [PubMed]
  • Peng SL, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest. 1997 Apr 15;99(8):1936–1946. [PMC free article] [PubMed]
  • Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest. 1998 Jan 15;101(2):364–371. [PMC free article] [PubMed]
  • Haas C, Ryffel B, Le Hir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol. 1997 Jun 1;158(11):5484–5491. [PubMed]
  • Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol. 1998 Jul 1;161(1):494–503. [PubMed]
  • Haas C, Ryffel B, Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol. 1998 Apr 15;160(8):3713–3718. [PubMed]
  • Clynes R, Dumitru C, Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science. 1998 Feb 13;279(5353):1052–1054. [PubMed]
  • Alleva DG, Kaser SB, Beller DI. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J Immunol. 1998 Dec 15;161(12):6878–6884. [PubMed]
  • Huang FP, Feng GJ, Lindop G, Stott DI, Liew FY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med. 1996 Apr 1;183(4):1447–1459. [PMC free article] [PubMed]
  • Fan X, Oertli B, Wüthrich RP. Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas(lpr) mice with renal injury. Kidney Int. 1997 Jan;51(1):79–86. [PubMed]
  • Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, Pippen AM, Ruiz P, Wood ER, Gilkeson GS. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med. 1994 Feb 1;179(2):651–660. [PMC free article] [PubMed]
  • Nakajima A, Hirose S, Yagita H, Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol. 1997 Feb 1;158(3):1466–1472. [PubMed]
  • McMurray RW, Hoffman RW, Nelson W, Walker SE. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus--analyses of strain, gender, and age effects. Clin Immunol Immunopathol. 1997 Sep;84(3):260–268. [PubMed]
  • Chen SY, Takeoka Y, Pike-Nobile L, Ansari AA, Boyd R, Gershwin ME. Autoantibody production and cytokine profiles of MHC class I (beta2-microglobulin) gene deleted New Zealand black (NZB) mice. Clin Immunol Immunopathol. 1997 Sep;84(3):318–327. [PubMed]
  • Ohteki T, Okamoto S, Nakamura M, Nemoto E, Kumagai K. Elevated production of interleukin 6 by hepatic MNC correlates with ICAM-1 expression on the hepatic sinusoidal endothelial cells in autoimmune MRL/lpr mice. Immunol Lett. 1993 May;36(2):145–152. [PubMed]
  • Alarcón-Riquelme ME, Möller G, Fernández C. Macrophage depletion decreases IgG anti-DNA in cultures from (NZB x NZW)F1 spleen cells by eliminating the main source of IL-6. Clin Exp Immunol. 1993 Feb;91(2):220–225. [PMC free article] [PubMed]
  • Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol. 1994 May;144(5):927–937. [PMC free article] [PubMed]
  • Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest. 1994 Aug;94(2):585–591. [PMC free article] [PubMed]
  • Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol. 1993 Jul;4(1):58–61. [PubMed]
  • Santiago ML, Fossati L, Jacquet C, Müller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med. 1997 Jan 6;185(1):65–70. [PMC free article] [PubMed]
  • Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994 Jan 1;179(1):305–310. [PMC free article] [PubMed]
  • Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. J Immunol. 1997 Sep 15;159(6):2658–2667. [PubMed]
  • Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995 Mar 1;181(3):839–844. [PMC free article] [PubMed]
  • Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest. 1997 Nov 15;100(10):2622–2633. [PMC free article] [PubMed]
  • Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 1988 Jan 28;331(6154):356–358. [PubMed]
  • Richter G, Qin ZH, Diamantstein T, Blankenstein T. Analysis of restriction fragment length polymorphism in lymphokine genes of normal and autoimmune mice. J Exp Med. 1989 Oct 1;170(4):1439–1443. [PMC free article] [PubMed]
  • Jacob CO, Tashman NB. Disruption in the AU motif of the mouse TNF-alpha 3' UTR correlates with reduced TNF production by macrophages in vitro. Nucleic Acids Res. 1993 Jun 11;21(11):2761–2766. [PMC free article] [PubMed]
  • Jacob CO, Lee SK, Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3'-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol. 1996 Apr 15;156(8):3043–3050. [PubMed]
  • Fujimura T, Hirose S, Jiang Y, Kodera S, Ohmuro H, Zhang D, Hamano Y, Ishida H, Furukawa S, Shirai T. Dissection of the effects of tumor necrosis factor-alpha and class II gene polymorphisms within the MHC on murine systemic lupus erythematosus (SLE). Int Immunol. 1998 Oct;10(10):1467–1472. [PubMed]
  • Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol. 1989 Dec 1;143(11):3470–3475. [PubMed]
  • Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H. Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem. 1993 Sep-Oct;16(5):233–243. [PubMed]
  • Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol. 1988 Nov 1;141(9):3050–3054. [PubMed]
  • Moore KJ, Yeh K, Naito T, Kelley VR. TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J Immunol. 1996 Jul 1;157(1):427–432. [PubMed]
  • Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int. 1995 Jan;47(1):122–130. [PubMed]
  • Alleva DG, Kaser SB, Beller DI. Aberrant cytokine expression and autocrine regulation characterize macrophages from young MRL+/+ and NZB/W F1 lupus-prone mice. J Immunol. 1997 Dec 1;159(11):5610–5619. [PubMed]
  • Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus. 1993 Dec;2(6):359–365. [PubMed]
  • Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum. 1993 Aug;36(8):1111–1120. [PubMed]
  • Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 1996 Nov;35(11):1067–1074. [PubMed]
  • Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol. 1995 May;26(5):558–564. [PubMed]
  • Jacob CO, Hwang F, Lewis GD, Stall AM. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine. 1991 Nov;3(6):551–561. [PubMed]
  • Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989 Sep;52(3):421–434. [PubMed]
  • Deguchi Y, Kishimoto S. Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol. 1991 Sep;85(3):392–395. [PMC free article] [PubMed]
  • Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996 May;4(5):445–454. [PubMed]
  • Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science. 1998 Aug 14;281(5379):1001–1005. [PubMed]
  • Su X, Zhou T, Yang P, Edwards CK, 3rd, Mountz JD. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum. 1998 Jan;41(1):139–149. [PubMed]
  • Edwards CK, 3rd, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol. 1996 Aug 15;157(4):1758–1772. [PubMed]
  • Watanabe Y, Jacob CO. Regulation of MHC class II antigen expression. Opposing effects of tumor necrosis factor-alpha on IFN-gamma-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell. J Immunol. 1991 Feb 1;146(3):899–905. [PubMed]
  • Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 1994 Sep 1;180(3):995–1004. [PMC free article] [PubMed]
  • Dörner T, Hucko M, Mayet WJ, Trefzer U, Burmester GR, Hiepe F. Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha. Ann Rheum Dis. 1995 Nov;54(11):904–909. [PMC free article] [PubMed]
  • Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol. 1990 Mar 1;144(5):1753–1758. [PubMed]
  • Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997 May 5;185(9):1573–1584. [PMC free article] [PubMed]
  • Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998 Dec;10(6):669–676. [PubMed]
  • Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. [PubMed]
  • Hunger RE, Carnaud C, Garcia I, Vassalli P, Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol. 1997 Jan;27(1):255–261. [PubMed]
  • Hunger RE, Müller S, Laissue JA, Hess MW, Carnaud C, Garcia I, Mueller C. Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55. J Clin Invest. 1996 Aug 15;98(4):954–961. [PMC free article] [PubMed]
  • Hill CM, Lunec J. The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Mol Aspects Med. 1996 Oct;17(5):455–509. [PubMed]
  • Jacob CO. Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch? Immunol Today. 1992 Apr;13(4):122–125. [PubMed]
  • Mao C, Singh AK. IL-1 beta gene expression in B cells derived from the murine MRL/lpr model of lupus. Autoimmunity. 1996;24(2):71–79. [PubMed]
  • Lebedeva TV, Singh AK. Increased responsiveness of B. cells in the murine MRL/lpr model of lupus nephritis to interleukin-1 beta. J Am Soc Nephrol. 1995 Jan;5(7):1530–1534. [PubMed]
  • Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R. Immunoregulation of SLE-like disease by the IL-1 receptor: disease modifying activity on BDF1 hybrid mice and MRL autoimmune mice. Agents Actions. 1993;39(Spec No):C117–C120. [PubMed]
  • Kiberd BA, Stadnyk AW. Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology. 1995 Aug;30(2):131–137. [PubMed]
  • Singh AK, Lebedeva TV. Interleukin-1 contributes to high level IgG production in the murine MRL/lpr lupus model. Immunol Invest. 1994 Aug;23(4-5):281–292. [PubMed]
  • Singh AK, Mao C, Lebedeva TV. In vitro role of IL-1 in heightened IgG, anti-DNA, and nephritogenic idiotype production by B cells derived from the murine MRL/lpr lupus model. Clin Immunol Immunopathol. 1994 Sep;72(3):410–415. [PubMed]
  • Lowrance JH, O'Sullivan FX, Caver TE, Waegell W, Gresham HD. Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med. 1994 Nov 1;180(5):1693–1703. [PMC free article] [PubMed]
  • Caver TE, O'Sullivan FX, Gold LI, Gresham HD. Intracellular demonstration of active TGFbeta1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFbeta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J Clin Invest. 1996 Dec 1;98(11):2496–2506. [PMC free article] [PubMed]

Figures and Tables

Figure 1
Schematic representation of replicative senescence in repeatedly activated autoreactive memory T cells.

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...